Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Abstract Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the
neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Abstract Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular
sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin …

Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients
with heart failure. The prevalence of heart failure with normal or near-normal ejection …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …